Infectious Disease Control
TaiMed Biologics Announces Results from Late-Breaking Phase 2a Data on Long-Acting HIV Maintenance Therapy at CROI 2025
TMB-365/TMB-380 Combination Demonstrates Viral Suspension Without the Need for Susceptibility Screening TaiMed Biologics will reshape HIV treatment management and seeks strategic collaborations with global pharmaceutical partners for the commercialization of its long-acting HIV maintenance thera...
2025-03-18 06:00
1996
Report: RSV-associated Hospitalisation Costs in Singapore Estimated at SGD 9,430 per Patient; Poses Financial Strain on At-risk Older Adults
* New findings from a recent white paper highlight the economic and healthcare burden posed by Respiratory Syncytial Virus (RSV) on at-risk older adults aged 60 years or over in select high-income APEC countriesand regions, includingAustralia, Hong Kong, Japan, and Singapore * Singapore had 3...
2025-03-11 11:45
2296
Shingles Awareness Week 2025: Shingles increases risk for heart attack and stroke; the disease also increases risk for hospitalisation more than thrice in people with diabetes
* People who have had shingles are at a 59% higher risk for heart attack and at a 35% higher risk for stroke compared to those who have not had shingles. * Adults aged 50 years or over are at high risk for shingles due to age-related decline in immunity and the risk further increases amongst t...
2025-02-26 14:45
2069
SK bioscience Initiates Global Clinical Trials of mRNA Japanese Encephalitis Vaccine Candidate
* SK bioscience's first mRNA vaccine candidate enters Phase 1/2 clinical trials inAustralia and New Zealand, with interim results expected by 2026 * Joint R&D project between SK and CEPI includes up to USD 40 million in initial funding support from CEPI * SK bioscience will expand its vaccin...
2025-02-25 21:00
2880
Lessons from Japan's AMR Response for the Global Community
https://iris.who.int/handle/10665/380481
2025-02-25 12:00
1726
AIM Vaccine Leverages AI to Advance mRNA Vaccine Development mRNA Shingles Vaccine Submits Clinical Trial Application
HONG KONG, Feb. 12, 2025 /PRNewswire/ -- AIM Vaccine Co., Ltd. (06660.HK), a leading PRC vaccine company, published an announcement onFebruary 11, 2025, announced that its independently developed mRNA shingles vaccine has been submitted for clinical trials to the Center for Drug Evaluation (CDE) ...
2025-02-12 13:15
2937
Sasakawa Leprosy Initiative to Boost Support for Indonesia
Yohei Sasakawa, WHO Goodwill Ambassador for Leprosy Elimination, Makes Announcement on World Leprosy Day 2025 TOKYO, Jan. 25, 2025 /PRNewswire/ -- On the occasion of World Leprosy Day 2025 onJanuary 26, WHO Goodwill Ambassador for Leprosy Elimination Yohei Sasakawa announces that the Sasakawa Le...
2025-01-25 11:00
5478
Dx&Vx Presents a New Paradigm for Next-Generation Infectious Disease Response with the Development of a Universal Vaccine
- Preparing for Phase 2 Global Trials of a Ferritin Platform-Based Virus-Like Particle Universal Coronavirus Vaccine - Based on the Excellent Safety and Immune Response in Phase 1 Clinical Results, with a Plan to Extend Administration Routes and Indications SEOUL, South Korea, Jan. 13, 2025 /PRNe...
2025-01-13 22:00
3424
DIOSynVax Announces a new Advisory Board as it drives the clinical development of its NextGen Influenza Vaccines including Bird-Flu
CAMBRIDGE, England and SAN DIEGO, Jan. 9, 2025 /PRNewswire/ -- DIOSynVax, a clinical-stage biotechnology company at the forefront of developing innovative, broadly protective vaccines, built on the safety demonstrated by its "First in Human" Coronavirus vaccine trial, to announce its new portfoli...
2025-01-09 03:48
3387
Dx&Vx, From mRNA Vaccines to Nanoparticle Vaccines era of Next-Generation Vaccines
* Introduction of a Universal Coronavirus Vaccine: A robust cross-immunity effect to combat virus mutations. SEOUL, South Korea, Jan. 8, 2025 /PRNewswire/ -- The COVID-19 pandemic has fundamentally transformed global healthcare systems and vaccine technologies. The accelerated approval and rapi...
2025-01-08 22:00
2676
Asieris and CDC Sign Investigational Product Supply Agreement for APL-1202 in Free-Living Amoeba Infections Treatment under Expanded Access Investigational New Drug Program
SHANGHAI, Jan. 6, 2025 /PRNewswire/ -- Asieris Pharmaceuticals (Stock Code: 688176.SH), a leading global biopharmaceutical company dedicated to advancing innovative therapies for genitourinary tumors and women's health with significant unmet medical needs, announced the signing of an investigatio...
2025-01-06 18:05
2162
Docquity and HCDC Partner to Strengthen Preventive Medicine Education for Thousands of HCPs in Vietnam
Through this multi-year initiative, HCDC will tap on Docquity's digital capabilities and reach to arm over 3,000 HCPs across diverse fields with breakthroughs in preventive medicine HO CHI MINH, Vietnam, Jan. 6, 2025 /PRNewswire/ -- Docquity, Southeast Asia's largest community of healthcare prof...
2025-01-06 11:00
3844
SCG Cell Therapy partners A*STAR to accelerate RNA-based therapeutic development in Singapore
* SCG Cell Therapy signed a Memorandum of Understanding (MoU) with A*STAR Bioprocessing Technology Institute (A*STAR BTI) and Nucleic Acid Therapeutics Initiative (NATi) to advance ribonucleic acid (RNA)-based therapeutic manufacturing process development and clinical translation. * The parti...
2024-12-23 09:00
3502
GSK Leads Global Forum in Bangkok to Address Respiratory Health Challenges
GSK hosted the third annual RespiVerse Meeting on December 13 and 14 in Bangkok, Thailand. The event brought together renowned international speakers and healthcare professionals from 17 countries to address pressing global challenges in respiratory diseases, focusing on innovative solutions and ...
2024-12-17 11:59
2534
SK bioscience Receives Approval for Global Clinical Trials of mRNA Japanese Encephalitis Vaccine Candidate
* SK bioscience's first mRNA vaccine candidate is expected to enter clinical trials inAustralia in February 2025, with interim results expected by 2026. * Joint R&D project between SK and CEPI includes up to USD 40 million in initial funding support from CEPI. * SK bioscience will respond to...
2024-12-12 21:00
3002
Partnership Established to Advance WHO's Road Map for Neglected Tropical Diseases 2021-2030
TOKYO and GENEVA, Dec. 11, 2024 /PRNewswire/ -- The Global Health Innovative Technology (GHIT) Fund and the World Health Organization (WHO) have signed a memorandum of understanding (MoU) to further expand their partnership to promote access to safe, effective and affordable drugs, vaccines and ...
2024-12-11 09:00
1825
Own Your Story with AwarerHOME™
Malaysia's HIV Oral Self-Test for Accessible and Confident Testing KUALA LUMPUR, Malaysia, Nov. 28, 2024 /PRNewswire/ -- Say hello to confidence and control with AwarerHOME™,Malaysia's first homegrown HIV Oral Self-Test. This accessible, no-mess, no-fuss solution offers something even more impor...
2024-11-28 16:34
2658
SK bioscience Announces Approval of Its Quadrivalent Influenza Vaccine in Indonesia
* This approval paves the way for exports to the world's fourth most populous
country.
* SK bioscience aims to continue to grow as a global vaccine brand beyond
Korea. SEONGNAM, South Korea, Oct. 23, 2024 /PRNewswire/ -- SK bioscience
2024-10-23 15:11
2743
City microbes surviving on disinfectants, research reveals
New research shows microbes are evolving to resist cleaners used to eliminate them. It also identifies novel strains living inHong Kong that were previously only found in Antarctic desert soil. SUZHOU, China, Oct. 18, 2024 /PRNewswire/ -- After the recent pandemic, our use of disinfectants has i...
2024-10-18 17:24
3501
Centivax Selects Global CDMO BioCina to Initiate cGMP Manufacturing of Revolutionary Universal Influenza Vaccine
ADELAIDE, South Australia, Oct. 9, 2024 /PRNewswire/ -- BioCina Pty Ltd., a global end-to-end biologics Contract Development and Manufacturing Organization (CDMO), announced a new partnership with Centivax, Inc., for a project involving cell line development, cell banking and plasmid DNA manufact...
2024-10-09 23:37
3356
Week's Top Stories
Most Reposted
Marina Bay precinct partners UOB, Marina Bay Sands and Singapore Tourism Board, together with Disney Cruise Line, to illuminate Singapore's skyline with a fireworks sky show
[Picked up by 328 media titles]
2026-02-19 14:30
Never Miss a Message: Agoda's Customer Support Now Travels With You
[Picked up by 322 media titles]
2026-02-24 12:00
NextFin Asia: A New Dedicated Fund for the Catapult: Inclusion SE Asia Program to Further Scale Inclusive Finance Fintechs in ASEAN
[Picked up by 311 media titles]
2026-02-23 08:00
Klook and Osaka Convention & Tourism Bureau sign MoU to advance inbound tourism and foster socio-economic development throughout Osaka Prefecture
[Picked up by 288 media titles]
2026-02-24 16:13
Vitafoods Asia 2026 Expands by 30%: A Bigger, More Dynamic Trade Event with Exciting New Features & Increased International Participation
[Picked up by 288 media titles]
2026-02-23 10:09